Unlock instant, AI-driven research and patent intelligence for your innovation.

About cyclin D protein inhibitor polypeptide and its application

An effective dose and injection technology, applied in the field of peptides for the treatment of mantle cell lymphoma, can solve the problems that have not yet been developed

Inactive Publication Date: 2016-05-11
常州市肿瘤医院
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no drug for the treatment of mantle cell lymphoma that has developed a mature CyclinD protein inhibitor polypeptide

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • About cyclin D protein inhibitor polypeptide and its application
  • About cyclin D protein inhibitor polypeptide and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Effect of CyclinD protein inhibitor polypeptide on the proliferation of human mantle cell lymphoma cell z138.

[0020] The MTT colorimetric method was used. The logarithmic growth of z138 cells was added to a 96-well culture plate at 1.0×105, and cultured for 24 hours. Different concentrations of the experimental drug CyclinD protein inhibitor polypeptide 3 and the positive control drug vincristine were added to the experimental wells and positive drug control wells; The same volume of solvent was added to the blank group. Set up five duplicate wells per well, culture for 48h, add MTT to each well at 0h, 2h, 8h, 14h, 20h, 24h, 36h, and 48h respectively, after 4h of action, add DMSO, incubate for 30min, and measure at 620nm in a microplate reader Absorbance A value, according to the formula tumor cell growth inhibition rate=(1-absorbance value of experimental group / absorbance value of control group)×100%. The maximum proliferation inhibition rate for z138 was 92.75%. ...

Embodiment 2

[0024] Effect of CyclinD protein inhibitor polypeptide 3 on proliferation of human mantle cell lymphoma cell G519.

[0025] The MTT colorimetric method was used. The logarithmic growth of G519 cells was added to a 96-well culture plate at 1.0×105, and cultured for 24 hours. The experimental wells and the positive drug control wells were respectively added with different concentrations of the experimental drug CyclinD protein inhibitor polypeptide 3 and the positive control drug vincristine; The same volume of solvent was added to the blank group. Set up five duplicate wells per well, culture for 48h, add MTT to each well at 0h, 2h, 8h, 14h, 20h, 24h, 36h, and 48h respectively, after 4h of action, add DMSO, incubate for 30min, and measure at 620nm in a microplate reader Absorbance A value, according to the formula tumor cell growth inhibition rate=(1-absorbance value of experimental group / absorbance value of control group)×100%. The maximum proliferation inhibition rate of Mi...

Embodiment 3

[0027] Inhibition of CyclinD protein inhibitor polypeptide 1 on human mantle cell lymphoma cell G519 xenograft tumor growth in nude mice

[0028] Take the human mantle cell lymphoma cell line G519 in the logarithmic growth phase, and prepare 5 × 10 cells under sterile conditions. 7 / ml cell suspension, inoculated subcutaneously in the right armpit of nude mice with 0.1ml. Use a vernier caliper to measure the diameter of the transplanted tumor in nude mice, and wait until the tumor grows to 100-200mm 3 Animals were then randomly grouped. Using the method of measuring tumor diameter, dynamically observe the anti-tumor effect of the tested polypeptide. Tumor diameter was measured every 2 days. The method of administration was by tail vein injection. The negative control group was injected with the same amount of normal saline once a day; the paclitaxel group was given 10 mg / kg once a week; the endostar group was given 2.5 mg / kg once a day; 10mg / kg, 5mg / kg, administered once ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicines, particularly a polypeptide capable of inhibiting expression of Cyclin D protein and treating amphicyte lymphoma. The sequence is SVSYFKCVQKEVLPSMRKIV which is a brand-new sequence. The polypeptide can be used for inhibiting cell proliferation and migration of amphicyte lymphoma cells G519 and z138 and treating amphicyte lymphoma, and has potential new medicine development value.

Description

technical field [0001] The invention relates to CyclinD protein inhibitor polypeptide 3 and application thereof, in particular to a polypeptide capable of inhibiting CyclinD protein expression and treating mantle cell lymphoma. Background technique [0002] Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma characterized by overexpression of t(11;14)(q13;q32) and cyclinD1. It is a moderately malignant lymphoma with a long-term survival rate of very low. It is common in the elderly, mostly in men, with a median age of 60 years. MCL is prone to recurrence and is the subtype of lymphoma with the lowest long-term survival rate, with a median survival period of 3 to 5 years. The clinical manifestations are aggressive, the disease progresses rapidly, and there are usually extensive lymph node involvement, and extranodal lesions are common, and the liver, spleen, peripheral blood, and bone marrow are often infiltrated, often accompanied by multiple gastrointestinal invol...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K7/08A61K38/10A61P35/00
Inventor 罗居东周希法陆忠华唐益庭汤华卢绪菁
Owner 常州市肿瘤医院